Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation
OwnerJerome Zeldis, Patricia Rohane +1inventors
InventorsJerome Zeldis, Patricia Rohane, Peter Schafer
Life of this patent
Estimating the term…
Abstract
Methods of treating, preventing, and managing airway inflammation and other airway or pulmonary diseases and disorders are disclosed. Specific methods comprise the administration of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, alone or in combination with a second active agent and/or other conventional therapies. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Claims19
A method of treating, preventing, or managing airway inflammation, which comprises administering to a patient in need of such treatment, prevention, or management a therapeutically or prophylactically effective amount of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
A method of treating, preventing, or managing an airway or pulmonary disease or disorder, which comprises administering to a patient in need of such treatment, prevention, or management a therapeutically or prophylactically effective amount of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the airway or pulmonary disease or disorder is giant bullae, acute bronchitis, chronic bronchitis, emphysema, reversible obstructive airway disease, nocturnal asthma, exercise induced bronchospasm, or interstitial pulmonary fibrosis.
A method of treating, preventing, or managing an airway or pulmonary disease or disorder, which comprises administering to a patient in need of such treatment, prevention, or management a therapeutically or prophylactically effective amount of a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a second active agent, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
- wherein the airway or pulmonary disease or disorder is respiratory failure, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, giant bullae, acute bronchitis, chronic bronchitis, emphysema, reversible obstructive airway disease, nocturnal asthma, exercise induced bronchospasm, or interstitial pulmonary fibrosis;
- and
- wherein the second active agent is an antibiotic, anticholinergic, antihistaminic agent, anti-inflammatory agent, antioxidant, antitussive agent, β2-agonist, calcium channel blocker, corticosteroid, immunomodulatory agent, immunosuppressive agent, leukotriene inhibitor, monoclonal antibody, mucolytic, muscle relaxant, PDE4 inhibitor, potassium channel opener, prostaglandin or an analog, sensory neuropeptide release inhibitor, tachykinin antagonist, or theophylline or a derivative thereof.
A pharmaceutical composition comprising a PDE4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and one or more second active agent, wherein the second active agent is an antibiotic, anticholinergic, antihistaminic agent, anti-inflammatory agent, antioxidant, antitussive agent, β2-agonist, calcium channel blocker, corticosteroid, immunomodulatory agent, immunosuppressive agent, leukotriene inhibitor, monoclonal antibody, mucolytic, muscle relaxant, PDE4 inhibitor, potassium channel opener, prostaglandin or an analog, sensory neuropeptide release inhibitor, tachykinin antagonist, or theophylline or a derivative thereof.
Dependencies are inferred from the claim text.